deferasirox has been researched along with Osteosarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Argenziano, M; Di Martino, M; Di Paola, A; Di Pinto, D; Perrotta, S; Pota, E; Punzo, F; Rossi, F; Tortora, C | 1 |
| Lv, H; Shang, P; Wang, S; Xue, Y; Zhang, G; Zhou, L; Zhou, S | 1 |
2 other study(ies) available for deferasirox and Osteosarcoma
| Article | Year |
|---|---|
Effects of Iron Chelation in Osteosarcoma.
Topics: Apoptosis; Benzoates; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deferasirox; Drug Therapy, Combination; Humans; Hydrazines; Iron Chelating Agents; Osteosarcoma; Pyrazoles; Treatment Outcome | 2021 |
Iron Chelator Induces Apoptosis in Osteosarcoma Cells by Disrupting Intracellular Iron Homeostasis and Activating the MAPK Pathway.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Deferasirox; Deferoxamine; Humans; Iron; MAP Kinase Signaling System; Mice; Osteosarcoma; Siderophores; Xenograft Model Antitumor Assays | 2021 |